Anika Therapeutics (ANIK) Intangibles (2010 - 2026)

Anika Therapeutics (ANIK) has reported Intangibles for 17 consecutive years, with $1.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Intangibles fell 89.2% year-over-year to $1.7 million in Q2 2026; TTM through Jun 2026 was $1.7 million, a 89.2% decrease from a year earlier, with the FY2025 full-year figure at $1.7 million, down 91.43% from the prior year.
• Intangibles was $1.7 million for Q2 2026 at Anika Therapeutics, roughly flat from $1.7 million in the prior quarter.
• Over five years, Intangibles peaked at $112.1 million in Q1 2022 and troughed at $1.7 million in Q1 2025.
• A 5-year average of $56.3 million and a median of $49.9 million in 2024 frame the typical range for Intangibles.
• Across the five-year window, Intangibles changed 0.0% in 2023 and tumbled 96.6% in 2025, its largest moves.
• Over 5 years, Intangibles stood at $112.1 million in 2022, then sank by 82.31% to $19.8 million in 2023, then changed by 0.0% to $19.8 million in 2024, then slumped by 91.43% to $1.7 million in 2025, then changed by 0.0% to $1.7 million in 2026.
• The last three Intangibles figures came in at $1.7 million (Q2 2026), $1.7 million (Q1 2026), and $1.7 million (Q4 2025), per Business Quant data.